Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Molecular basis for LDL receptor recognition by PCSK9.

Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J.

Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1820-5. doi: 10.1073/pnas.0712064105. Epub 2008 Feb 4.

2.

Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding.

Gu HM, Adijiang A, Mah M, Zhang DW.

J Lipid Res. 2013 Dec;54(12):3345-57. doi: 10.1194/jlr.M041129. Epub 2013 Oct 8.

3.

Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.

Kosenko T, Golder M, Leblond G, Weng W, Lagace TA.

J Biol Chem. 2013 Mar 22;288(12):8279-88. doi: 10.1074/jbc.M112.421370. Epub 2013 Feb 11.

4.

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor.

Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13045-50. doi: 10.1073/pnas.0806312105. Epub 2008 Aug 27.

5.

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.

Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH.

J Biol Chem. 2007 Jun 22;282(25):18602-12. Epub 2007 Apr 23.

6.

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH.

Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, Carfí A.

EMBO Rep. 2011 Dec 1;12(12):1300-5. doi: 10.1038/embor.2011.205.

7.

A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.

Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, Bottomley MJ, Ruggeri L, Cummings RT, Cubbon RM, Santoro JC, Ehrhardt A, Lewis D, Fisher TS, Ha S, Njimoluh L, Wood DD, Hammond HA, Wisniewski D, Volpari C, Noto A, Lo Surdo P, Hubbard B, Carfí A, Sitlani A.

J Biol Chem. 2010 Apr 23;285(17):12882-91. doi: 10.1074/jbc.M110.113035. Epub 2010 Feb 19.

8.

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

Urban D, Pöss J, Böhm M, Laufs U.

J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. Review.

9.

New hypotheses about the structure-function of proprotein convertase subtilisin/kexin type 9: analysis of the epidermal growth factor-like repeat A docking site using WaterMap.

Pearlstein RA, Hu QY, Zhou J, Yowe D, Levell J, Dale B, Kaushik VK, Daniels D, Hanrahan S, Sherman W, Abel R.

Proteins. 2010 Sep;78(12):2571-86. doi: 10.1002/prot.22767.

PMID:
20589640
10.

PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.

Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA.

Biochem Biophys Res Commun. 2008 Oct 10;375(1):69-73. doi: 10.1016/j.bbrc.2008.07.106. Epub 2008 Jul 31.

PMID:
18675252
11.

Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.

Tveten K, Holla ØL, Cameron J, Strøm TB, Berge KE, Laerdahl JK, Leren TP.

Hum Mol Genet. 2012 Mar 15;21(6):1402-9. doi: 10.1093/hmg/ddr578. Epub 2011 Dec 8.

PMID:
22156580
12.

An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.

Schiele F, Park J, Redemann N, Luippold G, Nar H.

J Mol Biol. 2014 Feb 20;426(4):843-52. doi: 10.1016/j.jmb.2013.11.011. Epub 2013 Nov 16.

PMID:
24252255
13.

LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.

Alghamdi RH, O'Reilly P, Lu C, Gomes J, Lagace TA, Basak A.

Eur J Med Chem. 2015 Mar 6;92:890-907. doi: 10.1016/j.ejmech.2015.01.022. Epub 2015 Jan 12.

PMID:
25679794
14.

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo.

Ni YG, Di Marco S, Condra JH, Peterson LB, Wang W, Wang F, Pandit S, Hammond HA, Rosa R, Cummings RT, Wood DD, Liu X, Bottomley MJ, Shen X, Cubbon RM, Wang SP, Johns DG, Volpari C, Hamuro L, Chin J, Huang L, Zhao JZ, Vitelli S, Haytko P, Wisniewski D, Mitnaul LJ, Sparrow CP, Hubbard B, Carfí A, Sitlani A.

J Lipid Res. 2011 Jan;52(1):78-86. doi: 10.1194/jlr.M011445. Epub 2010 Oct 19.

15.

A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor.

Yamamoto T, Lu C, Ryan RO.

J Biol Chem. 2011 Feb 18;286(7):5464-70. doi: 10.1074/jbc.M110.199042. Epub 2010 Dec 11.

16.

Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.

McNutt MC, Kwon HJ, Chen C, Chen JR, Horton JD, Lagace TA.

J Biol Chem. 2009 Apr 17;284(16):10561-70. doi: 10.1074/jbc.M808802200. Epub 2009 Feb 17.

17.

Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor.

Holla ØL, Laerdahl JK, Strøm TB, Tveten K, Cameron J, Berge KE, Leren TP.

Biochem Biophys Res Commun. 2011 Mar 11;406(2):234-8. doi: 10.1016/j.bbrc.2011.02.023. Epub 2011 Feb 13.

PMID:
21324305
18.

Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.

Geschwindner S, Andersson GM, Beisel HG, Breuer S, Hallberg C, Kihlberg BM, Lindqvist AM, O'Mahony G, Plowright AT, Raubacher F, Knecht W.

Protein Eng Des Sel. 2015 May;28(5):117-25. doi: 10.1093/protein/gzv008. Epub 2015 Mar 4.

PMID:
25744035
19.

Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor.

Zhang Y, Eigenbrot C, Zhou L, Shia S, Li W, Quan C, Tom J, Moran P, Di Lello P, Skelton NJ, Kong-Beltran M, Peterson A, Kirchhofer D.

J Biol Chem. 2014 Jan 10;289(2):942-55. doi: 10.1074/jbc.M113.514067. Epub 2013 Nov 13.

20.

Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants.

Bottomley MJ, Cirillo A, Orsatti L, Ruggeri L, Fisher TS, Santoro JC, Cummings RT, Cubbon RM, Lo Surdo P, Calzetta A, Noto A, Baysarowich J, Mattu M, Talamo F, De Francesco R, Sparrow CP, Sitlani A, Carfí A.

J Biol Chem. 2009 Jan 9;284(2):1313-23. doi: 10.1074/jbc.M808363200. Epub 2008 Nov 10.

Supplemental Content

Support Center